financetom
Business
financetom
/
Business
/
--Pfizer, BioNTech Say Influenza Vaccine Candidate Met One of Two Primary Objectives in Phase 3 Trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Pfizer, BioNTech Say Influenza Vaccine Candidate Met One of Two Primary Objectives in Phase 3 Trial
Aug 16, 2024 4:17 AM

06:51 AM EDT, 08/16/2024 (MT Newswires) --

Price: 28.88, Change: +0.17, Percent Change: +0.59

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved